April 1st 2025
Novavax’s COVID-19 vaccine, Merck’s RSV antibody, and Innoviva’s gonorrhea antibiotic await regulatory decisions this quarter.
Hepatitis C and the Dwindling of Research Funding
March 14th 2017Hepatitis C virus is the world’s most prevalent blood-borne viral infection for which a vaccine does not exist. To eliminate HCV infection on a global scale, experts argue that vaccine development needs to become a public health priority.
Read More
Is it Time for a Global Vaccine Injury Compensation System?
February 21st 2017In order to ensure that vaccines reach those who need them the most, experts are proposing a global vaccine injury compensation system that would ensure their safety in the event of adverse reactions from vaccines developed on shortened timelines.
Read More